Updated:
YuanBio Venture
YuanBio Venture, a Suzhou-based healthcare VC, has backed over 200 life-science companies and achieved 19 IPOs since 2013.
YuanBio Venture
Founded in 2013 and anchored in Suzhou's bioBAY, YuanBio Venture emerged as a dedicated healthcare investment firm targeting early and growth-stage opportunities. The firm was built by a team of operator-investors with backgrounds spanning biomedical research, entrepreneurship, and venture capital. Its principals — including 林艺, who holds a PhD in immunology and molecular biology from Columbia and an MBA from Chicago — combine scientific depth with company-building experience. YuanBio Venture deploys capital across four verticals: 新药创制 (novel drug discovery), 医疗器械 (medical devices), 诊断&精准医疗 (diagnostics and precision medicine), and 医疗服务 (healthcare services). The firm has built over 200 portfolio positions, with 19 exits via the Hong Kong Stock Exchange, Shanghai's STAR Market, and other boards. Its investment approach is stage-agnostic within the healthcare continuum, spanning seed through late-stage expansion. The firm's physical location inside bioBAY gives it early visibility into companies emerging from the park's 600+ biotech tenants. Named portfolio companies include 博生吉 (PersonGen), 昆翎 (ClinChoice), and 帝迈 (Dymind). With a team of scientist-investors and an expert advisor network, YuanBio Venture has been repeatedly ranked among China's top 10 healthcare VC funds and most active healthcare investors by industry data providers. In June 2024, the firm was recognized as a top-30 most active early-stage investor and top-20 most active healthcare investor by 第一新声 (FirstVoice). It maintains four internal platform networks — drugs, devices, diagnostics, and services — designed to share expertise and resources across its 60+ active portfolio companies and bioBAY's broader ecosystem. YuanBio Venture's structural edge lies in its symbiosis with bioBAY, a government-backed industrial park that functions as both a captive deal pipeline and an operational resource for portfolio companies. Rather than competing for access across China's fragmented healthcare market, the firm sits at the center of a self-reinforcing cluster where entrepreneurs, labs, regulators, and clinical trial infrastructure are co-located — a model closer to Kendall Square or Mission Bay's biotech density than a conventional VC office.
General information
Firm type
Private Equity
Year founded
2013
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Suzhou
Corporate office
Suzhou, China
Principals
林艺
Investment Team Member
陈杰
Investment Team Member
高维鹏
Investment Team Member
班博
Investment Team Member
成岗
Investment Team Member
Sector focus
Frequently asked questions
How does YuanBio Venture source its investment opportunities?
The firm is physically headquartered inside Suzhou's bioBAY industrial park, which houses over 600 biotech companies. This co-location provides direct, early access to founders and spinouts emerging from the park's research infrastructure, giving YuanBio a proprietary sourcing channel not available to firms outside bioBAY.
Which healthcare subsectors does YuanBio Venture focus on?
YuanBio Venture invests across four primary verticals: novel drug discovery, medical devices, diagnostics and precision medicine, and healthcare services. The firm has built dedicated platform networks within each vertical to support portfolio companies with technical expertise and industry connections.
What stage of companies does YuanBio Venture target?
The firm invests from seed and start-up through expansion and late-stage growth, maintaining a stage-agnostic approach within the healthcare sector. This flexibility allows it to continue supporting portfolio companies from early development through pre-IPO rounds.
How many companies has YuanBio Venture backed, and how many have gone public?
The firm reports over 200 portfolio investments and 19 companies that have listed on public markets, including the Hong Kong Stock Exchange and Shanghai's STAR Market (per the firm). Named public companies in its portfolio include PersonGen, ClinChoice, and Dymind.
What is YuanBio Venture's relationship with bioBAY?
YuanBio Venture operates from within bioBAY, Suzhou's major biotech industrial park, and leverages the park's infrastructure and tenant network as a core part of its investment strategy. bioBAY provides access to deal flow, post-investment operational support, and a collaborative ecosystem of entrepreneurs and researchers.
Who are the key investment decision-makers at YuanBio Venture?
The firm's website lists a scientific and investment team that includes 林艺 (PhD, Columbia; MBA, Chicago), 陈杰 (MBA, Cornell), 高维鹏 (law degree, Peking University; EMBA, CEIBS), 班博, and 成岗. The firm does not publicly designate a single CIO or managing partner title, presenting the group as a collective of operator-investors.
Does YuanBio Venture invest outside of China?
The firm describes itself as 'rooted in bioBAY and radiating globally.' While its headquarters and primary focus remain on China's healthcare market, the firm's posture and advisor network suggest international co-investment and cross-border deal capability, though specific non-China investments are not publicly detailed.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: